Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14995338 | 0.81 | PTGS2 (0.36) | PTGS2MTNR1AMTNR1BHTR2C | |
| SCHEMBL3229950 | 0.79 | PTGS2 (0.40) | PTGS2MTNR1AMTNR1BHTR2CPOLB | |
| SCHEMBL3214187 | 0.79 | PTGS2 (0.37) | PTGS2MTNR1AMTNR1BHTR2C | |
| SCHEMBL3400408 | 0.78 | POLB (0.40) | PTGS2MTNR1AMTNR1BHTR2CPOLB | |
| SCHEMBL3213697 | 0.77 | MTNR1A (0.40) | PTGS2MTNR1AMTNR1BHTR2CPOLB | |
| SCHEMBL1711841 | 0.74 | MTNR1A (0.41) | PTGS2MTNR1AMTNR1BHTR2CPOLB | |
| SCHEMBL1711924 | 0.74 | PTGS2 (0.39) | PTGS2MTNR1AMTNR1BHTR2CPOLB | |
| SCHEMBL1837381 | 0.74 | MTNR1A (0.36) | PTGS2MTNR1AMTNR1BHTR2C | |
| SCHEMBL3406526 | 0.74 | ERN1 (0.41) | PTGS2MTNR1AMTNR1BHTR2CPOLB | |
| SCHEMBL1711854 | 0.73 | MTNR1A (0.35) | PTGS2MTNR1AMTNR1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| EP-2136807-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008125594-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | PTGS2 213/4885MTNR1A 1695/4885MTNR1B 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.